To translate this research into clinical impact, Brano Therapeutics, through its licensing agreement with Duke-NUS, draws on the School’s scientific expertise, research platforms and datasets to accelerate the development of these therapies. 

The US$6.8 million seed round includes a US$380,000 (S$500,000) commitment from Duke-NUS’ LIVE Ventures, an early stage innovation fund and incubation programme that helps bridge the gap between academic discovery and commercial development. This is LIVE Ventures’ first direct investment in a spin-off company, underscoring Duke-NUS’ confidence in Brano Therapeutics’ strategy and science. 

Professor Wang Yibin, Director of the Cardiovascular & Metabolic Disorders Programme at Duke-NUS Medical School and Scientific Founder of Brano Therapeutics, said:

“Our study shows that the failure of the specific nutrient processing pathway plays a key role in the development of Heart Failure with preserved Ejection Fraction and is a distinct feature of the disease. Restoring this metabolic pathway could provide a promising new treatment. We are deeply grateful for the trust placed in us by our investors and look forward to advancing this discovery toward novel therapies for patients.” >>Read more

Source: Duke-NUS Communications
For more information, please visit www.branotherapeutics.com.